Pegaptanib sodium for the treatment of diabetic macular oedema
 
Status Suspended
Process STA
Referral date 01 March 2011
Topic area
  • Endocrine, nutritional and metabolic
  • Eye
Description

NICE has been informed by the manufacturer of Pegaptanib, Pfizer, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 8 November 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.

Scoped within Batch 16

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: TBC
Project manager:

Lori Farrar

Technical Lead: Helen Tucker

Timeline

Key events during the development of the guidance:

Date Update
29 July 2011 NICE has been informed by the manufacturer of Pegaptanib, Pfizer, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 8 November 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance